British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

GlaxoSmithKline said it would buy cancer-focused drug company Tesaro for about $4.16 billion, positioning the health-care giant in a promising, but fiercely competitive, area of medicine.

GlaxoSmithKline downgraded full-year earnings expectations, as its second-quarter profit was hit by currency moves, weak sales of its respiratory drugs and the continuing bribery investigation in ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

As I looked into the story at the time, several things became clear: GlaxoSmithKline was promoting the drug for use by teenagers even though it had never been cleared by the FDA for anyone under ...

Photo by Flickr user Ian Wilson Doctors will no longer be paid to speak on behalf of GlaxoSmithKline and its products, the British drug maker said Tuesday. In addition, the pharmaceutical company ...

Pharmaceutical comipany GlaxoSmithKline is under scrutiny following the death of children in Argentina. Parents believe that the experimental vaccines may be the cause of infant deaths.

GlaxoSmithKline's chief executive officer said in an email to the company’s employees that Slaoui’s name would be removed from its research and development facility in Rockville, Md.

GlaxoSmithKline wants to better understand biology so it can discover more medicines, like every other drugmaker. It also wants to quit wasting money on drug candidates that look promising in the ...